Clinical trials
Leukemia clinical trials
Cancer of the blood and bone marrow that affects how blood cells are made. We’re tracking 1,284 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03418038RecruitingPhase 2
Vitamin C with chemotherapy for lymphoma and blood disorders
This trial tests whether adding high-dose vitamin C (ascorbic acid) to standard chemotherapy helps treat lymphomas that have come back or not responded, as well as two related blood disorders (CCUS and CMML). The goal is to see if the vitamin C makes the chemo work better.
Mankato, MinnesotaAges 18 years+ - NCT03383575RecruitingPhase 2
Azacitidine plus enasidenib for IDH2-mutant MDS
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
Baltimore, MarylandAges 12 years+ - NCT03226704Enrolling by invitation
Leukapheresis to prepare CAR cell therapy
This trial collects white blood cells through a procedure called leukapheresis to help make CAR or other adoptive cell therapies. It’s for people with certain cancers who are not in remission (or are at high risk of relapse) and can meet health and lab requirements.
Bethesda, MarylandAges 3–65 - NCT03188874Recruiting
Registry study for adults with AML and collected samples
This study enrolls adults with acute myeloid leukemia (AML) to build a detailed registry and store biological samples. It helps researchers understand AML better and may support future studies.
Baden-Baden, Baden-WurttembergAges 18 years+ - NCT03104491RecruitingPhase 1/Phase 2
Inotuzumab after transplant for CD22-positive leukemia
This trial studies inotuzumab ozogamicin, a leukemia-targeting medicine, given after an allogeneic stem cell transplant. It’s for people with CD22-positive acute lymphoblastic leukemia (ALL) to help prevent relapse and improve outcomes after transplant.
Westwood, KansasAges 16–75 - NCT03280888Recruiting
Blood cells and chronic myelomonocytic leukemia study
This research study examines blood cells from patients with chronic myelomonocytic leukemia (CMML), a rare blood cancer, to better understand how the disease develops and progresses. By studying your blood cells, researchers hope to learn more about what causes CMML and how to treat it better.
NiceAges 18 years+ - NCT03113643RecruitingPhase 1
SL-401 with standard drugs for hard-to-treat blood cancers
This Phase 1 study tests SL-401, given with azacitidine and sometimes venetoclax, to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN). It aims to find a safe dose and see whether the combination can improve blood cancer control.
Duarte, CaliforniaAges 18 years+ - NCT03050268Recruiting
Study of childhood cancer risk in families
This study looks at inherited (family) risk for childhood cancers, including families with early cancers or known cancer risk conditions. It may help researchers understand why some children get cancer and improve future risk detection and care.
Memphis, TennesseeAges Any age - NCT03150693RecruitingPhase 3
New treatment for young adults with CD22-positive ALL
This Phase 3 trial tests adding inotuzumab ozogamicin to standard chemotherapy for newly diagnosed CD22-positive B-cell acute lymphoblastic leukemia (ALL). It may help more patients achieve remission and reduce the risk of the leukemia coming back, while also checking safety and tolerability.
Birmingham, AlabamaAges 18–39 - NCT03058588Recruiting
Genetic testing study for inherited AML or MDS risk
This study uses advanced DNA testing to look for inherited gene changes in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It may help explain whether your illness could be part of a family-linked risk syndrome, which can guide treatment and family planning.
BresciaAges Any age - NCT03013998RecruitingPhase 2/Phase 3
Personalized treatment study for acute myeloid leukemia
This study matches people with acute myeloid leukemia (AML) to treatments based on their specific genetic markers. It aims to find the most effective therapy with fewer side effects compared to standard care.
Phoenix, ArizonaAges 18 years+ - NCT02877303RecruitingPhase 2
Frontline drug treatment for newly diagnosed B-cell leukemia
This trial tests a combination of targeted and chemotherapy medicines as first treatment for newly diagnosed B-cell acute lymphoblastic leukemia (ALL) or related lymphoblastic lymphoma. It aims to improve how well treatment controls the leukemia and how long people can stay in remission.
Houston, TexasAges 14 years+ - NCT02677064Recruiting
Study on barriers to stem cell transplant for acute leukemia
This study looks at what makes it hard for people with acute leukemia or related blood cancers to get a stem cell transplant. It aims to find ways to help more people get this treatment.
Hartford, ConnecticutAges 18–80 - NCT02646839Enrolling by invitationPhase 2
Testing a gene-matched transplant approach for childhood leukemia
This trial studies a specific type of partially matched (haploidentical) stem cell transplant in children with ALL, AML, or MDS. It looks at whether using certain immune system gene patterns (KIR) and measuring leftover disease after treatment can improve outcomes and cost-effectiveness.
Los Angeles, CaliforniaAges Up to 21 years - NCT02560883Recruiting
Hairy cell leukemia patient data registry
This registry collects information about people with classic and variant hairy cell leukemia. It helps doctors learn from real-world patient data and may improve future care.
Miami, FloridaAges 18 years+ - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Birmingham, AlabamaAges Any age - NCT01515527RecruitingPhase 2
Cladribine plus low-dose cytarabine and decitabine for AML or MDS
This Phase 2 study tests a combination chemotherapy plan (cladribine, low-dose cytarabine, and decitabine) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to shrink the leukemia/MDS and improve outcomes, including for certain people who may not tolerate standard treatment.
Houston, TexasAges 60 years+ - NCT01853631RecruitingPhase 1
CAR T-cell therapy for CD19-positive B-cell blood cancers
This Phase 1 study tests a personalized form of immune therapy called CAR T cells that are designed to recognize CD19, a marker on certain B-cell cancers. It may help people with difficult-to-treat (recurrent or relapsed) B-cell lymphoma or leukemia (ALL/CLL).
Houston, TexasAges Up to 75 years - NCT01409161RecruitingPhase 2
Tretinoin and arsenic drugs for newly diagnosed acute promyelocytic leukemia
This trial studies how well a combination of tretinoin (ATRA) and arsenic trioxide (ATO)—with or without another antibody-like drug called gemtuzumab—treats people with newly diagnosed acute promyelocytic leukemia (APL). The goal is to see if these medicines work better together and are safe.
Houston, TexasAges 10 years+ - NCT00816114Recruiting
Chart review for CML patients previously treated with certain pills
This study reviews existing medical records of people with chronic myelogenous leukemia (CML) who were treated with specific FDA-approved targeted tablets (tyrosine kinase inhibitors) at MD Anderson but not on an MD Anderson clinical trial. It may help the hospital understand how these medicines are used in real-world care.
Houston, TexasAges Any age - NCT00501826RecruitingPhase 2
Check nelarabine plus chemotherapy for T-cell blood cancers
This trial tests a combination of chemotherapy with nelarabine in people with T-cell acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma. It may help by improving remission in newly diagnosed or certain previously treated patients whose disease did not respond after one initial treatment.
Houston, TexasAges Any age - NCT00186147Enrolling by invitation
Bone marrow grafting for leukemia and lymphoma
This study involves bone marrow cell grafting for people affected by leukemia or lymphoma. You may be eligible if you are a transplant recipient or a donor and you freely choose to take part.
Stanford, CaliforniaAges 18–70 - NCT00923442Enrolling by invitation
Study of blood cancers’ biology using stored or new tissue
This trial studies how different blood cancers and early (pre-cancer) blood conditions work, using tumor/blood tissue samples. It may help researchers learn more about disease biology for future treatments, with little to no extra risk if samples come from routine care.
Bethesda, MarylandAges 1–120 - NCT07877610RecruitingPhase 1/Phase 2
Engineered immune cells for leukemia that has not responded to treatment
This trial tests a new type of cell therapy for people with a fast-growing blood cancer (AML or BPDCN) that has not improved with standard treatments. The therapy uses specially modified immune cells (called CAR T cells) to target and kill cancer cells. It may be an option for those who have run out of other treatment choices.
Monza, MBAges 6 months–75 years
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia?
- Yes. Clin2 currently lists 1,284 recruiting leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.